Argenica Therapeutics Ltd has released a press release.
Final Phase1 Clinical Trial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- Latest Preclinical HIE Study Results
- Significant Non-Dilutive Funding For Preclinical HIE Studies
- Interim Phase 1 Safety Report Confirms Safety of ARG-007
- Non-Dilutive Funding Received to Progress Alzheimers Studies
- Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers
Later from Argenica Therapeutics
- Argenica Successfully Completes $4.0m Placement
- ARG-007 Protects Brain Cells in Moderate TBI Model
- ARG-007 Phase 2 Clinical Trial Update
- Investor Presentation
- ARG-007 Prevents Uptake & Aggregation of Key Protein
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics